Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
Silicon Valley Research Institute
2091
mi
from 43215
San Jose, CA
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
Silicon Valley Research Institute
2091
mi
from 43215
San Jose, CA
Click here to add this to my saved trials
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
Tufts Medical Center
642
mi
from 43215
Boston, MA
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
Tufts Medical Center
642
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
University of Miami
992
mi
from 43215
Miami, FL
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
University of Miami
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
Queen's Medical Center
4501
mi
from 43215
Honolulu, HI
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
Queen's Medical Center
4501
mi
from 43215
Honolulu, HI
Click here to add this to my saved trials
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
Northwestern University
274
mi
from 43215
Chicago, IL
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
Xiaoli Ma, PC
416
mi
from 43215
Philadelphia, PA
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
Xiaoli Ma, PC
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
Royal Prince Alfred Hospital
9459
mi
from 43215
Camperdown,
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
Royal Prince Alfred Hospital
9459
mi
from 43215
Camperdown,
Click here to add this to my saved trials
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
St. Louis University
397
mi
from 43215
Saint Louis, MO
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
St. Louis University
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated:  9/29/2017
Northwell Health
493
mi
from 43215
Manhasset, NY
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
Status: Enrolling
Updated: 9/29/2017
Northwell Health
493
mi
from 43215
Manhasset, NY
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3
Status: Enrolling
Updated:  10/4/2017
Southern California Research Center
1954
mi
from 43215
Coronado, CA
Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3
Status: Enrolling
Updated: 10/4/2017
Southern California Research Center
1954
mi
from 43215
Coronado, CA
Click here to add this to my saved trials
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated:  10/5/2017
Family and Medical Counseling Service
330
mi
from 43215
Washington, D.C.,
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated: 10/5/2017
Family and Medical Counseling Service
330
mi
from 43215
Washington, D.C.,
Click here to add this to my saved trials
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated:  10/5/2017
Unity Health Care/Walker Jones
330
mi
from 43215
Washington, D.C.,
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated: 10/5/2017
Unity Health Care/Walker Jones
330
mi
from 43215
Washington, D.C.,
Click here to add this to my saved trials
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated:  10/5/2017
Whitman Walker Clinic
327
mi
from 43215
Washington, D.C.,
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated: 10/5/2017
Whitman Walker Clinic
327
mi
from 43215
Washington, D.C.,
Click here to add this to my saved trials
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B
Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B
Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity
Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity
Status: Enrolling
Updated:  10/9/2017
Center for Liver Diseases, UPMC.
165
mi
from 43215
Pittsburgh, PA
Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity
Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity
Status: Enrolling
Updated: 10/9/2017
Center for Liver Diseases, UPMC.
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus
Status: Enrolling
Updated:  10/13/2017
Southern California Research Center
1954
mi
from 43215
Coronado, CA
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus
Status: Enrolling
Updated: 10/13/2017
Southern California Research Center
1954
mi
from 43215
Coronado, CA
Click here to add this to my saved trials
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus
Status: Enrolling
Updated:  10/13/2017
Auckland Clinical Studies
8359
mi
from 43215
Auckland,
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus
Status: Enrolling
Updated: 10/13/2017
Auckland Clinical Studies
8359
mi
from 43215
Auckland,
Click here to add this to my saved trials
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus
Status: Enrolling
Updated:  10/13/2017
Bach and Godofsky Infectious Diseases
862
mi
from 43215
Bradenton, FL
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus
Status: Enrolling
Updated: 10/13/2017
Bach and Godofsky Infectious Diseases
862
mi
from 43215
Bradenton, FL
Click here to add this to my saved trials
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus
Status: Enrolling
Updated:  10/13/2017
Gastro One
501
mi
from 43215
Germantown, TN
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus
Status: Enrolling
Updated: 10/13/2017
Gastro One
501
mi
from 43215
Germantown, TN
Click here to add this to my saved trials
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  10/16/2017
Clinical Research Facility
1964
mi
from 43215
Costa Mesa, CA
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 10/16/2017
Clinical Research Facility
1964
mi
from 43215
Costa Mesa, CA
Click here to add this to my saved trials
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  10/16/2017
Clinical Research Facility
1964
mi
from 43215
Pasadena, CA
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 10/16/2017
Clinical Research Facility
1964
mi
from 43215
Pasadena, CA
Click here to add this to my saved trials
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  10/16/2017
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 10/16/2017
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  10/16/2017
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 10/16/2017
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  10/16/2017
7988
mi
from 43215
Hong Kong,
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 10/16/2017
7988
mi
from 43215
Hong Kong,
Click here to add this to my saved trials
Prevention of Recurrent Hepatitis B After Liver Transplantation
Prevention of Recurrent Hepatitis B After Liver Transplantation
Status: Enrolling
Updated:  10/16/2017
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Prevention of Recurrent Hepatitis B After Liver Transplantation
Prevention of Recurrent Hepatitis B After Liver Transplantation
Status: Enrolling
Updated: 10/16/2017
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Patient-Centered Care and Asian Americans
A Patient-Centered Intervention to Increase Screening of Hepatitis B and C Among Asian Americans
Status: Enrolling
Updated:  10/24/2017
San Francisco General Hospital
2107
mi
from 43215
San Francisco, CA
Patient-Centered Care and Asian Americans
A Patient-Centered Intervention to Increase Screening of Hepatitis B and C Among Asian Americans
Status: Enrolling
Updated: 10/24/2017
San Francisco General Hospital
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Patient-Centered Care and Asian Americans
A Patient-Centered Intervention to Increase Screening of Hepatitis B and C Among Asian Americans
Status: Enrolling
Updated:  10/24/2017
UCSF
2108
mi
from 43215
San Francisco, CA
Patient-Centered Care and Asian Americans
A Patient-Centered Intervention to Increase Screening of Hepatitis B and C Among Asian Americans
Status: Enrolling
Updated: 10/24/2017
UCSF
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Thousand Asian American Study
Thousand Asian American Study (TAAS)
Status: Enrolling
Updated:  10/27/2017
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Thousand Asian American Study
Thousand Asian American Study (TAAS)
Status: Enrolling
Updated: 10/27/2017
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Status: Enrolling
Updated:  10/31/2017
Kaiser Permanente
2108
mi
from 43215
San Francisco, CA
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Status: Enrolling
Updated: 10/31/2017
Kaiser Permanente
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Status: Enrolling
Updated:  10/31/2017
Univ. Of Miami School Of Medicine/Center For Liver Diseases
993
mi
from 43215
Miami, FL
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Status: Enrolling
Updated: 10/31/2017
Univ. Of Miami School Of Medicine/Center For Liver Diseases
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Status: Enrolling
Updated:  10/31/2017
The Ichan School of Medicine at Mount Sinai
480
mi
from 43215
New York, NY
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Status: Enrolling
Updated: 10/31/2017
The Ichan School of Medicine at Mount Sinai
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Status: Enrolling
Updated:  10/31/2017
Texas Liver Institute
1136
mi
from 43215
San Antonio, TX
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Status: Enrolling
Updated: 10/31/2017
Texas Liver Institute
1136
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
The Office of Dr. Franco Antonio Felizarta, M.D.
1980
mi
from 43215
Bakersfield, CA
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
The Office of Dr. Franco Antonio Felizarta, M.D.
1980
mi
from 43215
Bakersfield, CA
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
AIDS Research Alliance
1978
mi
from 43215
Los Angeles, CA
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
AIDS Research Alliance
1978
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
University of California Davis Research
2043
mi
from 43215
Sacramento, CA
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
University of California Davis Research
2043
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Community AIDS Resource Inc dba Care Resource
996
mi
from 43215
Miami, FL
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Community AIDS Resource Inc dba Care Resource
996
mi
from 43215
Miami, FL
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
University of South Florida Health - HIV Clinical Research Unit
831
mi
from 43215
Tampa, FL
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
University of South Florida Health - HIV Clinical Research Unit
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Rowan Tree Medical, P.A.
968
mi
from 43215
Wilton Manors, FL
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Rowan Tree Medical, P.A.
968
mi
from 43215
Wilton Manors, FL
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
University of Iowa Hospitals and Clinics
460
mi
from 43215
Iowa City, IA
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
University of Iowa Hospitals and Clinics
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Saint Michael's Medical Center
468
mi
from 43215
Newark, NJ
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Saint Michael's Medical Center
468
mi
from 43215
Newark, NJ
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
New York Medical College
491
mi
from 43215
Valhalla, NY
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
New York Medical College
491
mi
from 43215
Valhalla, NY
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
I.D. Consultants, P.A.
348
mi
from 43215
Charlotte, NC
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
I.D. Consultants, P.A.
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Kaiser Permanente Sunnybrook Medical Office
2022
mi
from 43215
Clackamas, OR
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Kaiser Permanente Sunnybrook Medical Office
2022
mi
from 43215
Clackamas, OR
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Kaiser Permanente Northwest
2026
mi
from 43215
Portland, OR
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Kaiser Permanente Northwest
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
University Health Care Center Downtown
1138
mi
from 43215
San Antonio, TX
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
University Health Care Center Downtown
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Alameda Health System, Highland Hospital
2097
mi
from 43215
Oakland, CA
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Alameda Health System, Highland Hospital
2097
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
University of California
2040
mi
from 43215
Sacramento, CA
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
University of California
2040
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials